<DOC>
	<DOC>NCT02234882</DOC>
	<brief_summary>The purpose of this study is to assess the effect of the coadministration of multiple doses of BMS-663068 on the systemic exposure of rosuvastatin.</brief_summary>
	<brief_title>Study on Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1. Signed Informed Consent Form Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocolrequired procedures. 2. Target Population Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, vital sign measurements, 12lead ECG measurements, and clinical laboratory test results. 3. Age and Reproductive Status Men and women of nonchildbearing potential, ages 18 to 50 years, inclusive. Women must have documented proof that they are not of childbearing potential. Women must not be breastfeeding. Males who are sexually active with women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s). Women who are of childbearing potential or breastfeeding Any significant acute or chronic medical illness History of rhabdomyolysis or biliary disorders, including Gilbert's disease or DubinJohnson disease Smokers (those who currently smoke, as well as those who have stopped smoking less than 6 months prior to the start of study drug administration) Alcohol intake exceeding 2 standard drinks per days; however, no alcohol is allowed 1 week prior to the start of study drug administration and for the duration of the study Any other sound medical, psychiatric, and/or social reason as determined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>